Tecon Biology Co Ltd
SZSE:002100
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
T
|
Tecon Biology Co Ltd
SZSE:002100
|
9.4B CNY |
Loading...
|
|
| US |
A
|
Archer-Daniels-Midland Co
XETRA:ADM
|
27.9B EUR |
Loading...
|
|
| US |
|
Bunge Ltd
NYSE:BG
|
23.7B USD |
Loading...
|
|
| SG |
|
Wilmar International Ltd
SGX:F34
|
22.1B SGD |
Loading...
|
|
| CN |
|
Tongwei Co Ltd
SSE:600438
|
81.1B CNY |
Loading...
|
|
| MY |
S
|
Sime Darby Plantation Bhd
KLSE:SIMEPLT
|
40.5B MYR |
Loading...
|
|
| US |
|
Darling Ingredients Inc
NYSE:DAR
|
8.1B USD |
Loading...
|
|
| US |
|
Ingredion Inc
NYSE:INGR
|
7.3B USD |
Loading...
|
|
| MY |
|
IOI Corporation Bhd
KLSE:IOICORP
|
24.6B MYR |
Loading...
|
|
| MY |
K
|
Kuala Lumpur Kepong Bhd
KLSE:KLK
|
22.3B MYR |
Loading...
|
|
| CN |
|
New Hope Liuhe Co Ltd
SZSE:000876
|
38.6B CNY |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Tecon Biology Co Ltd
Glance View
Tecon Biology Co Ltd has carved its niche in the rapidly evolving biotechnology sector, specializing in the development and production of bio-based products and solutions. At its core, the company leverages advanced biological science to create environmentally friendly products that satisfy a range of industrial needs. Operating at the intersection of science and sustainability, Tecon has focused its efforts on the use of microbial fermentation technology and genetic engineering to produce bio-products that support agricultural, pharmaceutical, and environmental applications. By advancing proprietary technological capabilities, the company has demonstrated a commitment to not only commercial success but also environmental stewardship, recognizing the increasing global emphasis on sustainable business practices. The company's financial model is centered around translating cutting-edge biological research into commercially viable products. Tecon Biology generates revenue by licensing its biotechnological innovations to major agricultural and pharmaceutical firms that seek sustainable and cost-effective alternatives to traditional chemical-based products. Additionally, Tecon manufactures and sells its own branded line of bio-products, such as bio-fertilizers and enzyme solutions, directly to end-users both domestically and internationally. This dual approach allows the company to capitalize on the growing demand for sustainable solutions while maintaining diverse revenue streams, thereby enhancing its resilience in the competitive biotech industry. Through strategic collaborations and continuous innovation, Tecon Biology has established itself as a formidable player in the global market, poised to address some of the biggest challenges facing the world today.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Tecon Biology Co Ltd is 3.9%, which is above its 3-year median of 0.4%.
Over the last 3 years, Tecon Biology Co Ltd’s Operating Margin has increased from -0.7% to 3.9%. During this period, it reached a low of -6.6% on Dec 31, 2023 and a high of 4.9% on Mar 31, 2025.